Belvedere Trading
AVIR icon

Belvedere Trading’s Atea Pharmaceuticals AVIR Stock Holding History

Belvedere Trading’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,500
Closed -$108K – 937
2022
Q4 		$108K Buy
+22,500
New +$114K ﹤0.01% 455
2022
Q1 		– Sell
-14,000
Closed -$90K – 467
2021
Q4 		$90K Buy
+14,000
New +$218K ﹤0.01% 318

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Belvedere Trading's AVIR Position: Q2 2024 in Review

Belvedere Trading sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 10,519 shares — an estimated $42.5K sold.

Belvedere Trading first reported a position in AVIR in Q4 2021 and held it in 2 quarters. The position peaked at $42.5K in Q1 2024. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

  • Belvedere Trading reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 10,519 Atea Pharmaceuticals shares in Q2 2024, an estimated $42.5K.
  • Belvedere Trading first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Belvedere Trading's Atea Pharmaceuticals position peaked at $42.5K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.